Among the bills signed by New York Governor Hochul at the close of 2021 – and in addition to the bill that significantly changed New York’s insurance disclosure requirements that was the focus of our previous posts, “Amendments to New York’s Onerous New Insurance Disclosure Requirements May Be Imminent” and Continue Reading New York Enacts New Rule of Evidence Expanding the Scope of the Admissibility of Employee-Agent Hearsay Statements
Amendments to New York’s Onerous New Insurance Disclosure Requirements May Be Imminent

In my last blog, we explored the onerous changes made by the New York State Legislature to the Defendant’s obligation to provide disclosure regarding available insurance. Entitled the Comprehensive Insurance Disclosure Act, the law made wholesale changes to CPLR 3101(f)’s insurance disclosure requirements and went into immediate effect upon the bill’s signing by Governor Hochul on December 31, 2021. Continue Reading Amendments to New York’s Onerous New Insurance Disclosure Requirements May Be Imminent
New York Ends the Year with Onerous New Insurance Coverage Disclosure Rules for Defendants in Product Liability Litigation

On December 31, 2021, New York Governor Kathy Hochul closed the year by signing into law the Comprehensive Insurance Disclosure Act (S7052) to impose sweeping changes to the rules embodied in New York Civil Practice Law and Rules (CPLR) section 3101(f) as they pertain to the disclosure of defendants’ insurance coverage in New York litigation.
California’s SB 447 – Increasing the Danger in One of the Country’s Most Favorable Venues for Personal Injury Plaintiffs

On October 1, 2021, California Governor Gavin Newsom signed into law SB 447, which amended California Code of Civil Procedure section 377.34 to permit wrongful death claimants in California to recover damages for decedents’ pain, suffering or disfigurement. Continue Reading California’s SB 447 – Increasing the Danger in One of the Country’s Most Favorable Venues for Personal Injury Plaintiffs
Delta-9 THC Products from Hemp Are a Risk Not Worth Taking
The hemp-derived cannabinoid market continues to grow and evolve despite lingering questions over federal legality and numerous state laws that try to keep pace. Much has been written about new “legal” hemp products that contain intoxicating delta-8 THC, delta-10 THC and THC-O Acetate. This article, however, seeks to highlight a brazen new use for familiar old delta-9 THC. Edible products with intoxicating levels of delta-9 THC now are being sold as legal and less-expensive alternatives to regulated cannabis products. Although purveyors of hemp-derived delta-9 THC seek to exploit a perceived loophole in the 2018 Farm Bill’s definition of hemp extracts, these unregulated and intoxicating products are fraught with risk. The cannabis and hemp industries and their insurers should take notice and respond now. Continue Reading Delta-9 THC Products from Hemp Are a Risk Not Worth Taking